Roche's Tecentriq enjoys first-mover advantage in adjuvant NSCLC

Retrieved on: 2021-10-21 23:39:03

Tags for this article:

Click the tags to see associated articles and topics

Roche's Tecentriq enjoys first-mover advantage in adjuvant NSCLC. View article details on hiswai:

Excerpt

Now following surgery, US patients with PD-L1 expression on ≥ 1% of tumour cells can be treated with Roche's Tecentriq (atezolizumab), ...

Article found on: www.clinicaltrialsarena.com